Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT5 | O14744 | 4/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | WDR77 | Q9BQA1 | 2/20 | 0.43 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | RAD52 | P43351 | 1/20 | 0.40 |
| ▸ | NLRP1 | Q9C000 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | TACR3 | P29371 | 1/20 | 0.39 |
| ▸ | GPR183 | P32249 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1344365 | 1.00 | PRMT5 (0.46) | PRMT5MEN1KMT2AALDH1A1LMNA | |
| SCHEMBL1343320 | 0.89 | GPR183 (0.50) | PRMT5ALDH1A1WDR77GPR183 | |
| SCHEMBL1343318 | 0.89 | GPR183 (0.50) | PRMT5ALDH1A1WDR77GPR183 | |
| SCHEMBL1344446 | 0.88 | GPR183 (0.43) | PRMT5WDR77GPR183 | |
| SCHEMBL1344443 | 0.88 | GPR183 (0.43) | PRMT5WDR77GPR183 | |
| SCHEMBL1344266 | 0.84 | MEN1 (0.47) | MEN1KMT2AALDH1A1LMNAACHE | |
| SCHEMBL1344264 | 0.84 | MEN1 (0.47) | MEN1KMT2AALDH1A1LMNAACHE | |
| SCHEMBL2902256 | 0.80 | GPR183 (0.52) | ALDH1A1GPR183 | |
| SCHEMBL2903272 | 0.80 | GPR183 (0.52) | ALDH1A1GPR183 | |
| SCHEMBL2902254 | 0.80 | GPR183 (0.52) | ALDH1A1GPR183 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8063042-B2 | Heterocyclic compounds | HOFFMANN-LA ROCHE INC. (US) | 2011-11-22 | — | — | US | disclosed |
| US-20090023713-A1 | HETEROCYCLIC COMPOUNDS | HOFFMANN-LA ROCHE, INC. | 2009-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023713-A1 | HETEROCYCLIC COMPOUNDS | CCR5, CCR3, CCR2 | PRMT5 823/4885MEN1 3201/4885KMT2A 4324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.